von der Maase H - Search Results

1

Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease.

Zachariae R, Pedersen CG, Jensen AB, Ehrnrooth E, Rossen PB, von der Maase H. Zachariae R, et al. Among authors: von der maase h. Br J Cancer. 2003 Mar 10;88(5):658-65. doi: 10.1038/sj.bjc.6600798. Br J Cancer. 2003. PMID: 12618870 Free PMC article.

2

Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma.

Mortensen MS, Bandak M, Kier MG, Lauritsen J, Agerbaek M, Holm NV, von der Maase H, Daugaard G. Mortensen MS, et al. Among authors: von der maase h. Cancer. 2017 Apr 1;123(7):1212-1218. doi: 10.1002/cncr.30458. Epub 2016 Nov 28. Cancer. 2017. PMID: 27893934 Free article.

3

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.

Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Schmidt H, et al. Among authors: von der maase h. Cancer. 2006 Mar 1;106(5):1130-9. doi: 10.1002/cncr.21678. Cancer. 2006. PMID: 16456816 Free article.

4

Radical radiotherapy for urinary bladder cancer: treatment outcomes.

Fokdal L, Høyer M, von der Maase H. Fokdal L, et al. Among authors: von der maase h. Expert Rev Anticancer Ther. 2006 Feb;6(2):269-79. doi: 10.1586/14737140.6.2.269. Expert Rev Anticancer Ther. 2006. PMID: 16445379 Review.

5

High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors.

Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Møller K, von der Maase H, Orntoft TF. Koed K, et al. Among authors: von der maase h. Cancer Res. 2005 Jan 1;65(1):34-45. Cancer Res. 2005. PMID: 15665277

6

Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer.

Fokdal L, Høyer M, Meldgaard P, von der Maase H. Fokdal L, et al. Among authors: von der maase h. Radiother Oncol. 2004 Aug;72(2):139-45. doi: 10.1016/j.radonc.2004.05.006. Radiother Oncol. 2004. PMID: 15297133

7

Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer.

Primdahl H, von der Maase H, Sørensen FB, Wolf H, Ørntoft TF. Primdahl H, et al. Among authors: von der maase h. J Cancer Res Clin Oncol. 2002 Jun;128(6):295-301. doi: 10.1007/s00432-002-0344-3. Epub 2002 Apr 27. J Cancer Res Clin Oncol. 2002. PMID: 12073046

8

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.

Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sorensen SM, Nishimura MI, von der Maase H. Duval L, et al. Among authors: von der maase h. Clin Cancer Res. 2006 Feb 15;12(4):1229-36. doi: 10.1158/1078-0432.CCR-05-1485. Clin Cancer Res. 2006. PMID: 16489078 Clinical Trial.

9

Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.

Donskov F, von der Maase H, Marcussen N, Hamilton-Dutoit S, Madsen HH, Jensen JJ, Hokland M. Donskov F, et al. Among authors: von der maase h. Clin Cancer Res. 2004 Dec 1;10(23):7911-6. doi: 10.1158/1078-0432.CCR-04-1111. Clin Cancer Res. 2004. PMID: 15585624

10

Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.

Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, Madsen HH, Fode K, von der Maase H. Donskov F, et al. Among authors: von der maase h. Cancer Immunol Immunother. 2004 Aug;53(8):729-39. doi: 10.1007/s00262-004-0525-9. Epub 2004 Apr 15. Cancer Immunol Immunother. 2004. PMID: 15088127 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results